Conv. Plasma
Nigella Sativa

All iota‑carrageenan studies
Meta analysis
study COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2

Morokutti-Kurz et al., International Journal of General Medicine, doi:10.2147/IJGM.S325861, NCT04533906
Sep 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective study of 31 subjects analyzing iota-carrageenan concentration in saliva after using an iota-carrageenan containing lozenge, showing sufficient concentration to neutralize common respiratory viruses including SARS-CoV-2. For SARS-CoV-2, the IC90 was exceeded by 121-fold (p < 0.001).
Morokutti-Kurz et al., 7 Sep 2021, prospective, peer-reviewed, 12 authors, trial NCT04533906 (history).
This PaperIota-carragee..All
The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2
Martina Morokutti-Kurz, Nicole Unger-Manhart, Philipp Graf, Pia Rauch, Julia Kodnar, Maximilian Große, Christian Setz, Markus Savli, Friedrich Ehrenreich, Andreas Grassauer, Eva Prieschl-Grassauer, Ulrich Schubert
International Journal of General Medicine, doi:10.2147/ijgm.s325861
The aim of this study was to investigate whether sucking of an iota-carrageenan containing lozenge releases sufficient iota-carrageenan into the saliva of healthy subjects to neutralize representatives of the most common respiratory virus families causing common cold and SARS-CoV-2. Patients and Methods: In this monocentric, open label, prospective clinical trial, 31 healthy subjects were included to suck a commercially available iota-carrageenan containing lozenge. Saliva samples from 27 subjects were used for ex vivo efficacy analysis. The study's primary objective was to assess if the mean iota-carrageenan concentration of the saliva samples exceeded 5 µg/mL, which is the concentration known to reduce replication of human rhinovirus (hRV) 1a and 8 by 90%. The iota-carrageenan concentration of the saliva samples was analyzed by UV-Vis spectroscopy. The antiviral effectiveness of the individual saliva samples was determined in vitro against a panel of respiratory viruses including hRV1a, hRV8, human coronavirus OC43, influenza virus A H1N1pdm09, coxsackievirus A10, parainfluenza virus 3 and SARS-CoV-2 using standard virological assays. Results: The mean iota-carrageenan concentration detected in the saliva exceeds the concentration needed to inhibit 90% of hRV1a and hRV8 replication by 134-fold (95% CI 116.3-160.8-fold; p < 0.001). Thus, the study met the primary endpoint. Furthermore, the iota-carrageenan saliva concentration was 60 to 30,351-fold higher than needed to reduce viral replication/binding of all tested viruses by at least 90% (p < 0.001). The effect was most pronounced in hCoV OC43; in case of SARS-CoV-2, the IC 90 was exceeded by 121-fold (p < 0.001). Conclusion: Sucking an iota-carrageenan containing lozenge releases sufficient iota-carrageenan to neutralize and inactivate the most abundant respiratory viruses as well as pandemic SARS-CoV-2. The lozenges are therefore an appropriate measure to reduce the viral load at the site of infection, hereby presumably limiting transmission within a population as well as translocation to the lower respiratory tract. Trial Registration: NCT04533906.
Disclosure Martina Morokutti-Kurz, Nicole Unger-Manhart, Philipp Graf, Julia Kodnar are employed by Marinomed Biotech AG. Eva Prieschl-Grassauer and Andreas Grassauer are co-founder of Marinomed Biotech AG and inventor on patent #WO2008067982 held by Marinomed Biotech AG that relates to the content of the manuscript. Markus Savli reports personal fees from Marinomed Biotech AG. Andreas Grassauer, Eva Prieschl-Grassauer and Martina Morokutti-Kurz are inventors of a patent submission related to the content of the manuscript; the number of this patent application is EP20186334. The authors report no other conflicts of interest in this work. International Journal of General Medicine Dovepress
Bansal, Jonsson, Taylor, Iota-carrageenan and xylitol inhibit SARS-CoV-2 in cell culture, bioRxiv, doi:10.1101/2020.08.19.225854
Charlton, Babady, Ginocchio, Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections, Clin Microbiol Rev, doi:10.1128/CMR.00042-18
Collins, Dawes, The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa, J Dent Res, doi:10.1177/00220345870660080201
Denny, The clinical impact of human respiratory virus infections, Am J Respir Crit Care Med, doi:10.1164/ajrccm/152.4_Pt_2.S4
Eccles, Iota-carrageenan as an antiviral treatment for the common cold, Open Virol J, doi:10.2174/1874357902014010009
Eccles, Meier, Jawad, Weinmüllner, Grassauer et al., Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir Res, doi:10.1186/1465-9921-11-108
Eccles, Winther, Johnston, Robinson, Trampisch et al., Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial, Respir Res, doi:10.1186/s12931-015-0281-8
Fazekas, Eickhoff, Pruckner, Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold, BMC Complement Altern Med, doi:10.1186/1472-6882-12-147
Figueroa, Lombardo, Dogliotti, Efficacy of a nasal spray containing iota-carrageenan in the prophylaxis of COVID, doi:10.1101/2021.04.13.21255409%A0
Graf, Bernkop-Schnürch, Egyed, Koller, Prieschl-Grassauer et al., Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis, Int J Gen Med, doi:10.2147/IJGM.S167123
Grassauer, Weinmuellner, Meier, Pretsch, Prieschl-Grassauer et al., Iota-carrageenan is a potent inhibitor of rhinovirus infection, Virol J, doi:10.1186/1743-422X-5-107
Große, Ruetalo, Businger, Evidence that quinine exhibits antiviral activity against SARS-CoV-2 infection in vitro, Preprints, doi:10.2147/IJGM.S325861
Hemilä, Chalker, Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: re-analysis of randomized trial data, Pharmacol Res Perspect
Huijghebaert, Vanham, Van Winckel, Allegaert, Does trypsin oral spray (Viruprotect ® / ColdZyme ® ) protect against COVID-19 and common colds or induce mutation? Caveats in medical device regulations in the European union, Int J Environ Res Public Health, doi:10.3390/ijerph18105066
Jang, Shin, Lee, Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2, Sci Rep, doi:10.1038/s41598-020-80896-9
Koenighofer, Lion, Bodenteich, Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med, doi:10.1186/2049-6958-9-57
Leibbrandt, Meier, König-Schuster, Iota-carrageenan is a potent inhibitor of influenza A virus infection, PLoS One, doi:10.1371/journal.pone.0014320
Ludwig, Enzenhofer, Schneider, Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial, Respir Res, doi:10.1186/1465-9921-14-124
Morokutti-Kurz, Dovepress Powered by TCPDF
Morokutti-Kurz, Fröba, Graf, Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro, PLoS One, doi:10.1371/journal.pone.0237480
Morokutti-Kurz, Graf, Prieschl-Grassauer, Amylmetacresol/ 2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat, Int J Gen Med, doi:10.2147/IJGM.S120665
Schütz, Conzelmann, Fois, Carrageenan containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures, Am J Physiol Lung Cell Mol Physiol, doi:10.1152/ajplung.00552.2020
Snell, New treatments for viral respiratory tract infectionsopportunities and problems, J Antimicrob Chemother, doi:10.1093/jac/47.3.251
Yasir, Goyal, Bansal, Sonthalia, StatPearls [Internet
{ 'DOI': '10.2147/ijgm.s325861', 'ISSN': ['1178-7074'], 'URL': '', 'author': [ {'affiliation': [], 'family': 'Morokutti-Kurz', 'given': 'Martina', 'sequence': 'first'}, {'affiliation': [], 'family': 'Unger-Manhart', 'given': 'Nicole', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Graf', 'given': 'Philipp', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Rauch', 'given': 'Pia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kodnar', 'given': 'Julia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Große', 'given': 'Maximilian', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Setz', 'given': 'Christian', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Savli', 'given': 'Markus', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ehrenreich', 'given': 'Friedrich', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Grassauer', 'given': 'Andreas', 'sequence': 'additional'}, { 'ORCID': '', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Prieschl-Grassauer', 'given': 'Eva', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schubert', 'given': 'Ulrich', 'sequence': 'additional'}], 'container-title': 'International Journal of General Medicine', 'container-title-short': 'IJGM', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 9, 6]], 'date-time': '2021-09-06T17:12:22Z', 'timestamp': 1630948342000}, 'deposited': { 'date-parts': [[2023, 11, 8]], 'date-time': '2023-11-08T11:34:46Z', 'timestamp': 1699443286000}, 'indexed': {'date-parts': [[2024, 2, 17]], 'date-time': '2024-02-17T17:41:04Z', 'timestamp': 1708191664861}, 'is-referenced-by-count': 6, 'issued': {'date-parts': [[2021, 9]]}, 'language': 'en', 'license': [ { 'URL': '', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 9, 1]], 'date-time': '2021-09-01T00:00:00Z', 'timestamp': 1630454400000}}], 'link': [ { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '301', 'original-title': [], 'page': '5241-5249', 'prefix': '10.2147', 'published': {'date-parts': [[2021, 9]]}, 'published-online': {'date-parts': [[2021, 9]]}, 'publisher': 'Informa UK Limited', 'reference': [ { 'DOI': '10.1164/ajrccm/152.4_Pt_2.S4', 'author': 'Denny', 'doi-asserted-by': 'publisher', 'first-page': 'S4', 'journal-title': 'Am J Respir Crit Care Med', 'key': 'ref1', 'volume': '152', 'year': '1995'}, { 'DOI': '10.1093/jac/47.3.251', 'author': 'Snell', 'doi-asserted-by': 'publisher', 'first-page': '251', 'journal-title': 'J Antimicrob Chemother', 'key': 'ref2', 'volume': '47', 'year': '2001'}, { 'DOI': '10.1186/1465-9921-11-108', 'author': 'Eccles', 'doi-asserted-by': 'publisher', 'first-page': '108', 'journal-title': 'Respir Res', 'key': 'ref3', 'volume': '11', 'year': '2010'}, { 'DOI': '10.1186/1472-6882-12-147', 'author': 'Fazekas', 'doi-asserted-by': 'publisher', 'first-page': '147', 'journal-title': 'BMC Complement Altern Med', 'key': 'ref4', 'volume': '12', 'year': '2012'}, { 'DOI': '10.1186/2049-6958-9-57', 'author': 'Koenighofer', 'doi-asserted-by': 'publisher', 'first-page': '57', 'journal-title': 'Multidiscip Respir Med', 'key': 'ref5', 'volume': '9', 'year': '2014'}, { 'DOI': '10.1186/1465-9921-14-124', 'author': 'Ludwig', 'doi-asserted-by': 'publisher', 'first-page': '124', 'journal-title': 'Respir Res', 'key': 'ref6', 'volume': '14', 'year': '2013'}, { 'DOI': '10.1186/s12931-015-0281-8', 'author': 'Eccles', 'doi-asserted-by': 'publisher', 'first-page': '121', 'journal-title': 'Respir Res', 'key': 'ref7', 'volume': '16', 'year': '2015'}, { 'DOI': '10.1101/2021.04.13.21255409\xa0', 'author': 'Figueroa', 'doi-asserted-by': 'publisher', 'journal-title': 'medRxiv', 'key': 'ref8', 'year': '2021'}, { 'DOI': '10.1186/1743-422X-5-107', 'author': 'Grassauer', 'doi-asserted-by': 'publisher', 'first-page': '107', 'journal-title': 'Virol J', 'key': 'ref9', 'volume': '5', 'year': '2008'}, { 'DOI': '10.1371/journal.pone.0014320', 'author': 'Leibbrandt', 'doi-asserted-by': 'publisher', 'first-page': 'e14320', 'journal-title': 'PLoS One', 'key': 'ref10', 'volume': '5', 'year': '2010'}, { 'DOI': '10.2147/IJGM.S120665', 'author': 'Morokutti-Kurz', 'doi-asserted-by': 'publisher', 'first-page': '53', 'journal-title': 'Int J Gen Med', 'key': 'ref11', 'volume': '10', 'year': '2017'}, { 'DOI': '10.1371/journal.pone.0237480', 'author': 'Morokutti-Kurz', 'doi-asserted-by': 'publisher', 'first-page': 'e0237480', 'journal-title': 'PLoS One', 'key': 'ref12', 'volume': '16', 'year': '2021'}, {'key': 'ref13', 'volume-title': 'StatPearls [Internet]', 'year': '2020'}, { 'DOI': '10.1101/2020.08.19.225854', 'author': 'Bansal', 'doi-asserted-by': 'publisher', 'journal-title': 'bioRxiv', 'key': 'ref14', 'year': '2020'}, { 'DOI': '10.1128/CMR.00042-18', 'author': 'Charlton', 'doi-asserted-by': 'publisher', 'first-page': 'e00042', 'journal-title': 'Clin Microbiol Rev', 'key': 'ref15', 'volume': '32', 'year': '2019'}, { 'DOI': '10.1152/ajplung.00552.2020', 'author': 'Schütz', 'doi-asserted-by': 'publisher', 'first-page': 'L750', 'journal-title': 'Am J Physiol Lung Cell Mol Physiol', 'key': 'ref16', 'volume': '320', 'year': '2021'}, { 'DOI': '10.2147/IJGM.S167123', 'author': 'Graf', 'doi-asserted-by': 'publisher', 'first-page': '275', 'journal-title': 'Int J Gen Med', 'key': 'ref17', 'volume': '11', 'year': '2018'}, { 'author': 'Große', 'first-page': '2020070102', 'journal-title': 'Preprints', 'key': 'ref18', 'year': '2020'}, { 'DOI': '10.2174/1874357902014010009', 'author': 'Eccles', 'doi-asserted-by': 'publisher', 'first-page': '9', 'journal-title': 'Open Virol J', 'key': 'ref19', 'volume': '14', 'year': '2020'}, { 'key': 'ref20', 'unstructured': 'World Health Organization.WHO Manual on Animal Influenza Diagnosis and ' 'Surveillance. Available from: ' ' ' 'Accessed August 31, 2021.'}, { 'DOI': '10.1002/prp2.810', 'author': 'Hemilä', 'doi-asserted-by': 'crossref', 'first-page': 'e00810', 'journal-title': 'Pharmacol Res Perspect', 'key': 'ref21', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1038/s41598-020-80896-9', 'author': 'Jang', 'doi-asserted-by': 'publisher', 'first-page': '821', 'journal-title': 'Sci Rep', 'key': 'ref22', 'volume': '11', 'year': '2021'}, { 'DOI': '10.3390/ijerph18105066', 'author': 'Huijghebaert', 'doi-asserted-by': 'publisher', 'first-page': '5066', 'journal-title': 'Int J Environ Res Public Health', 'key': 'ref23', 'volume': '18', 'year': '2021'}, { 'DOI': '10.1177/00220345870660080201', 'author': 'Collins', 'doi-asserted-by': 'publisher', 'first-page': '1300', 'journal-title': 'J Dent Res', 'key': 'ref24', 'volume': '66', 'year': '1987'}], 'reference-count': 24, 'references-count': 24, 'relation': {}, 'resource': { 'primary': { 'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and ' 'Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2', 'type': 'journal-article', 'volume': 'Volume 14'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop